PA
ETTX

Parallel Advisors’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Parallel Advisors’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-600
Closed -$7K – 2353
2018
Q3 		$7K Buy
+600
New +$6.31K ﹤0.01% 1615

Other funds holding ETTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallel Advisors's ETTX Position: Q4 2018 in Review

Parallel Advisors sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q4 2018, closing a stake of 600 shares — an estimated $7K sold.

Parallel Advisors first reported a position in ETTX in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 20 funds tracked by Wall St. Rank hold ETTX as of Q4 2018.

  • Parallel Advisors reported no remaining Entasis Therapeutics Holdings Inc. position as of Q4 2018 after selling out during the quarter.
  • Parallel Advisors sold 600 Entasis Therapeutics Holdings Inc. shares in Q4 2018, an estimated $7K.
  • Parallel Advisors first reported a position in Entasis Therapeutics Holdings Inc. in Q3 2018 and held it in 1 quarter.
  • Parallel Advisors's Entasis Therapeutics Holdings Inc. position peaked at $7K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q4 2018.

Based on Parallel Advisors's 13F filing for Q4 2018, filed 5 Feb 2019.